Literature DB >> 43803

The pathochemistry of kernicterus.

R P Wennberg, C E Ahlfors, L F Rasmussen.   

Abstract

The stoichiometry of bilirubin--albumin interaction has been analyzed and quantitated in several recent studies, confirming that albumin binding of bilirubin obeys the law of mass action [4, 5, 14, 16, 26, 36, 43, 46, 61, 65, 73, 92, 111]. These studies provide a basis for interpreting bilirubin transport, cell uptake and toxicity from physicochemical and pharmacologic perspectives [35, 42, 58, 59]. In this report, we propose a model of the pathogenesis of kernicterus which views serum albumin and tissue as competing with each other for binding the miscible bilirubin pool. Evidence is presented to show that bilirubin normally binds reversibly to cellular membranes and certain soluble enzymes just as it does to albumin; the unbound bilirubin concentration is the driving force for both albumin and tissue binding. We propose that albumin binding is determined by the concentration of free bilirubin anion (which is essentially unaffected by physiologic pH changes), and that tissue binding is mainly determined by the concentration of free bilirubin acid (which is greatly influenced by pH). When bilirubin--tissue complexes are formed, essential cell functions may be inhibited, producing cellular acidosis, irreversible intracellular aggregation of bilirubin, and cell death. In developing this argument, we will sequentially discuss relevant features of bilirubin chemistry, the binding of bilirubin to albumin, the formation of bilirubin--tissue complexes, bilirubin toxicity, alternative viewpoints of bilirubin transport, and, finally, the implications of this model to the clinical management of jaundiced infants. It should be emphasized that this paper is an attempt to analyze bilirubin transport and toxicity using basic chemical principles; it is an extension of previously published proposals [17, 77], and will undoubtedly require further modification as additional experimental data becomes available.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 43803     DOI: 10.1016/0378-3782(79)90047-1

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  8 in total

Review 1.  Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns.

Authors:  Jon F Watchko
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

2.  Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.

Authors:  Kevin A Strauss; Charles E Ahlfors; Kyle Soltys; George V Mazareigos; Millie Young; Lauren E Bowser; Michael D Fox; James E Squires; Patrick McKiernan; Karlla W Brigatti; Erik G Puffenberger; Vincent J Carson; Hendrik J Vreman
Journal:  Hepatology       Date:  2020-02-05       Impact factor: 17.425

Review 3.  Newborn jaundice technologies: unbound bilirubin and bilirubin binding capacity in neonates.

Authors:  Sanjiv B Amin; Angelo A Lamola
Journal:  Semin Perinatol       Date:  2011-06       Impact factor: 3.300

4.  Interaction of bilirubin with human erythrocyte membranes.

Authors:  H Sato; S Kashiwamata
Journal:  Biochem J       Date:  1983-02-15       Impact factor: 3.857

Review 5.  Bilirubin Binding Capacity in the Preterm Neonate.

Authors:  Sanjiv B Amin
Journal:  Clin Perinatol       Date:  2016-02-28       Impact factor: 3.430

6.  Bilirubin binding to normal and modified human erythrocyte membranes: effect of phospholipases, neuraminidase, trypsin and CaCl2.

Authors:  I Rashid; M Owais; S Tayyab
Journal:  Mol Cell Biochem       Date:  2001-12       Impact factor: 3.396

Review 7.  Neonatal bilirubin toxicity. A review of kernicterus and the implications of drug-induced bilirubin displacement.

Authors:  P C Walker
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

8.  Bilirubin binding by variant albumins in Yanomama Indians.

Authors:  F W Lorey; C E Ahlfors; D G Smith; J V Neel
Journal:  Am J Hum Genet       Date:  1984-09       Impact factor: 11.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.